Provided by Tiger Fintech (Singapore) Pte. Ltd.

Johnson & Johnson

170.74
-0.3000-0.18%
Post-market: 170.15-0.5900-0.35%19:59 EDT
Volume:7.93M
Turnover:1.35B
Market Cap:411.20B
PE:18.29
High:171.56
Open:170.54
Low:169.65
Close:171.04
Loading ...

Jefferies Keeps Their Hold Rating on J & J Snack Foods (JJSF)

TIPRANKS
·
7 hours ago

How Pacira BioSciences’ (PCRX) Johnson & Johnson MedTech Collaboration Is Shaping Its Market Reach

Simply Wall St.
·
Yesterday

Why Drug Prices for Some Big Medicines Will Remain High for a Longer Time -- WSJ

Dow Jones
·
03 Aug

The 3 Things That Matter for Johnson & Johnson Now

Motley Fool
·
02 Aug

Buy Graham Holdings Stock. Its Parts Are Worth More Than the Whole. -- Barrons.com

Dow Jones
·
02 Aug

Court upholds 'Texas two-step' bankruptcy for Georgia-Pacific unit mired in lawsuits

Reuters
·
02 Aug

Moderna quarterly sales beat Street estimates on COVID booster sales, cost cuts

Reuters
·
01 Aug

BUZZ-Pharmaceutical shares fall after White House says Trump urging cos to lower drug costs

Reuters
·
01 Aug

Johnson & Johnson to Present at Morgan Stanley Global Healthcare Conference

Reuters
·
31 Jul

Boston Jury Awards Record $42M Verdict Against Johnson & Johnson in Asbestos Baby Powder Case

Reuters
·
30 Jul

Johnson & Johnson ordered to pay $42M after jury finds talc caused man’s cancer

Reuters
·
30 Jul

Johnson & Johnson Receives FDA 510(k) Clearance for VIRTUGUIDE™ AI-Powered System to Streamline Bunion Surgery

Reuters
·
29 Jul

Johnson & Johnson Launches Virtuguide™ AI-Powered Patient-Matched Lapidus System in U.S. to Reduce Complexity in Bunion Surgery for Millions

THOMSON REUTERS
·
29 Jul

Johnson & Johnson Submits sBLA to FDA for TREMFYA® Label Update to Include Inhibition of Joint Damage in Psoriatic Arthritis

Reuters
·
29 Jul

Johnson & Johnson Files With U.S. FDA to Include New Evidence in Tremfya® (Guselkumab) Label as the Only Il-23 Inhibitor to Demonstrate Significant Inhibition of Joint Structural Damage in Active Psoriatic Arthritis

THOMSON REUTERS
·
29 Jul

5 high-quality ASX ETFs to buy in August

MotleyFool
·
29 Jul

Got $1,000? 3 High-Yield Healthcare Stocks to Buy and Hold Forever

Motley Fool
·
29 Jul

These 3 Dow Stocks Are Set to Soar in 2025 and Beyond

Motley Fool
·
27 Jul

3 strong ASX ETFs to buy for simple investing

MotleyFool
·
27 Jul

How Johnson & Johnson Stock (JNJ) Discovered a New Lease of Life

TIPRANKS
·
26 Jul